by World Health Organization 2024 Cited by 747A second-line TB medicine (or drug) is an agent reserved for the treatment of drug-resistant TB. First-line TB medicines used to treat drug-susceptible TB –
Drug-resistant TB disease is caused by TB bacteria that are resistant to the drugs normally used to treat the disease. Drug-resistant TB is transmitted in the same way as drug-susceptible TB, and it is no more infectious than drug-susceptible TB.
There are several known interactions between drugs used to treat HIV and drug-resistant TB: TB medicines for treatment of patients with DR TB. This
TB cases with resistance to the two main anti-TB drugs, rifampicin TB drugs such as fluoroquinolones, are defined as pre-XDR-TB.
on treatment with: (i) new anti-TB drugs; (ii) novel MDR-TB regimens; or (iii) extensively drug- resistant TB (XDR-TB) regimens, in order to detect, manage
Types. There are several types of drug-resistant TB disease. Mono-resistant TB disease is caused by TB bacteria that are resistant to one TB treatment drug. Poly-resistant TB disease is caused by TB bacteria that are resistant to at least two TB drugs (but not both isoniazid and rifampin).
Drug-resistant TB means that some drugs initially used to treat TB will no longer be able to fight the TB germs in your body. TB that is resistant to more than one drug, called multidrug-resistant TB (MDR TB) is very dangerous. The treatment for this type of TB takes much longer, 20 to 30 months to complete, and you may experience more side
A second-line TB medicine (or drug) is an agent reserved for the treatment of drug-resistant TB. First-line TB medicines used to treat drug-susceptible TB ethambutol, isoniazid and pyrazinamide may also be used in MDR-TB regimens (streptomycin is now considered a second-line TB medicine
A second-line TB medicine (or drug) is an agent reserved for the treatment of drug-resistant TB. First-line TB medicines used to treat drug-susceptible TB ethambutol, isoniazid and pyrazinamide may also be used in MDR-TB regimens (streptomycin is now considered a second-line TB medicine
Comments